Rosen's Breast Pathology, 4e

408

Chapter 11

271. Charteris AA. On the changes in the mammary gland preceding carci- noma. J Pathol 1930;33:101–117. 272. Lagios MD, Westdahl PR, Rose MR. The concept and implications of multicentricity in breast carcinoma. Pathol Annu 1981;16:1123–1130. 273. Hardman PDJ, Worth A, Lee U. The risk of occult invasive breast can- cer after excisional biopsy showing in-situ ductal carcinoma of com- edo pattern. Can J Surg 1989;32:56–60. 274. Ashikari R, Huvos AG, Snyder RE. Prospective study of non-infiltrat- ing carcinoma of the breast. Cancer 1977;39:435–439. 275. Gallager HS, Martin JE. Early phases in the development of breast can- cer. Cancer 1969;24:1170–1178. 276. Morgenstern L, Kaufman PA, Friedman ND. The case against tylec- tomy for carcinoma of the breast. The factor of multicentricity. Am J Surg 1975;130:251–258. 277. Silverstein MJ, Rosser RJ, Gierson ED, et al. Axillary lymph node dissection for intraductal carcinoma: is it indicated? Cancer 1987;59:1819–1824. 278. Schwartz GF, Patchefsky AS, Feig SA, et al. Multicentricity of non- palpable breast cancer. Cancer 1980;45:2913–2916. 279. Hollingsworth AB, Stough RG. Multicentric and contralateral invasive tumors identified with pre-op MRI in patients newly diagnosed with ductal carcinoma in situ of the breast. Breast J 2012;18:420–427. 280. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:3248–3258. 281. Yerushalmi R, Tyldesley S, Woods R, et al. Is breast-conserving ther- apy a safe option for patients with tumor multicentricity and multifo- cality? Ann Oncol 2012;23:876–881. 282. Ozzello J, Sentipak P. Epithelial-stromal junction of intraductal carci- noma of the breast. Cancer 1970;26:1186–1198. 283. Ozzello L. Ultrastructure of intra-epithelial carcinomas of the breast. Cancer 1971;28:1508–1515. 284. Rajan PB, Perry RH. A quantitative study of patterns of basement membrane in ductal carcinoma in situ (DCIS) of the breast. Breast J 1995;1:315–321. 285. Tamimi SO, Ahmed A. Stromal changes in early invasive and non-invasive breast carcinoma: an ultrastructural study. J Pathol 1986;150:43–49. 286. Barsky SH, Togo S, Garbisa S, et al. Type IV collagenase immunoreac- tivity in invasive breast carcinoma. Lancet 1983;1:296–297. 287. Nakano S, Iyama K, Ogawa M, et al. Differential tissular expression and localization of type IV collagen alpha-1(IV), alpha-5(IV), and alpha-6(IV) chains and their mRNA in normal breast and in benign and malignant breast tumors. Lab Invest 1999;79:281–292. 288. Hewitt RE, Powe DG, Morrell K, et al. Laminin and collagen IV sub- unit distribution in normal and neoplastic tissues of colorectum and breast. Br J Cancer 1997;75:221–229. 289. Frazier TG, Copeland EM, Gallager HS, et al. Prognosis and treatment in minimal breast cancer. Am J Surg 1977;133:697–701. 290. Gallager HS, Martin JE. An orientation to the concept of minimal breast cancer. Cancer 1971;28:1505–1507. 291. Hutter RVP. The pathologist’s role in minimal breast cancer. Cancer 1971;28:1527–1536. 292. Ozzello L. The behaviour of basement membranes in intraductal car- cinoma of the breast. Am J Pathol 1959;35:887–799. 293. Dewar R, Fadare O, Gilmore H, et al. Best practices in diagnostic im- munohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med 2011;135:422–429. 294. Pusztaszeri M. Phenotypic alterations in myoepithelial cells of the breast in normal and pathologic conditions . Am J Surg Pathol 2010;34:1886. 295. Coyne J, Haboubi NY. Micro-invasive breast carcinoma with granulo- matous stromal response. Histopathology 1992;20:184–185. 296. Prasad ML, Hyjek E, Giri DD, et al. Double immunolabeling with cy- tokeratin and smooth-muscle actin in confirming early invasive carci- noma of breast. Am J Surg Pathol 1999;23:176–181. 297. Hou L, Sneige N, Hunt KK, et al. Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and rec- ommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer 2006;107:1760–1768. 298. King TA, Farr GH Jr, Cederbom GI, et al. A mass on breast imaging predicts coexisting invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ . Am Surg 2001;67:907–912.

299. BagnallMJ, Evans AJ,WilsonAR, et al. Predicting invasion inmammo- graphically detected microcalcification. Clin Radiol 2001;56:828–832. 300. Hoorntje LE, Schipper ME, Peeters PH, et al. The finding of inva- sive cancer after a preoperative diagnosis of ductal carcinoma in situ : causes of ductal carcinoma in situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 2003;10:748–753. 301. Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ : a guide to selective use of sentinel lymph node biopsy in management of duc- tal carcinoma in situ . J Am Coll Surg 2005;200:516–526. 302. Cowen PN. Recognition of intraduct mammary carcinoma. J Clin Pathol 1980;33:797. 303. Cowen PN, Bates C. The significance of intraduct appearances in breast cancer. Clin Oncol 1984;10:67–72. 304. Barsky SH, Doberneck SA, Sternlicht MD, et al. ‘Revertant’ DCIS in hu- man axillary breast carcinoma metastases. J Pathol 1997;183:188–194. 305. Arihiro K, Inai K, Kurihara K, et al. Distribution of laminin, type IV collagen and fibronectin in the invasive component of breast carci- noma. Acta Pathol Japonica 1993;43:758–764. 306. Nadji M, Nassiri M, Fresno M, et al. Laminin receptor in lymph node negative breast carcinoma. Cancer 1999;85:432–436. 307. Solin LJ, Fowble BL, Yeh I-T,et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive ir- radiation. Int J Radiat Oncol Biol Phys 1992;23:961–968. 308. Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with mi- croinvasion. Cancer 1998;82:2382–2390. 309. de Mascarel I, MacGrogan G, Mathoulin-Pelissier S, et al. Breast duc- tal carcinoma in situ with microinvasion. A definition supported by a long-term study of 1248 serially sectioned ductal carcinomas. Cancer 2002;94:2134–2142. 310. Jimenez RE, Visscher DW. Clinicopathologic analysis of microscopi- cally invasive breast carcinoma. Hum Pathol 1998;29:1412–1419. 311. Walker RA, Dearing SJ, Brown LA. Comparison of pathological and biological features of symptomatic and mammographically detected ductal carcinoma in situ of the breast. Hum Pathol 1999;30:943–948. 312. Prasad ML, Osborne MP, Giri DD, et al. Microinvasive carcinoma (T1 mic ) of the breast. Clinicopathologic profile of 21 cases. Am J Surg Pathol 2000;24:422–428. 313. Ross DS, Hoda SA. Microinvasive (T1 mic ) lobular carcinoma of the breast: clinicopathologic profile of 16 cases. Am J Surg Pathol 2011;35:750–756. 314. Shapiro-Wright HM, Julian TB. Sentinel lymph node biopsy and man- agement of the axilla in ductal carcinoma in situ . J Natl Cancer Inst Monogr 2010;2010(41):145–149. 315. Moore KH, Sweeney KJ, Wilson ME, et al. Outcomes for women with ductal carcinoma- in-situ and a positive sentinel node: a multi-institu- tional audit. Ann Surg Oncol 2007;14:2911–2917. 316. Intra M, Rotmensz N, Veronesi P, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the ex- perience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg 2008;247:315–319. 317. Zavotsky J, Hansen N, Brennan MB, et al. Lymph node metas- tasis from ductal carcinoma in situ with microinvasion. Cancer 1999;85:2439–2443. 318. Dauway EL, Giuliano R, Pendas S, et al. Lymphatic mapping: a tech- nique providing accurate staging for breast cancer. Breast Cancer 1999;6:145–154. 319. Wilkie C, White L, Dupont E, et al. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ . Am J Surg 2005;190:563–566. 320. Katz A, Gage I, Evans S, et al. Sentinel lymph node positivity of pa- tients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 2006;191:761–766. 321. Sakr R, Barranger E, Antoine M, et al. Ductal carcinoma in situ : value of sentinel lymph node biopsy. J Surg Oncol 2006;94:426–430. 322. Leidenius M, Salmenkivi K, von Smitten K, et al. Tumour-positive sentinel node findings in patients with ductal carcinoma in situ . J Surg Oncol 2006;94:380–384. 323. Huo l, Resetkova A, Lopez A, et al. Sentinel lymph node (SLN) sam- pling in patients with core biopsy diagnosis of ductal carcinoma in situ (DCIS): UT M.D. Anderson Cancer Center experience and future recommendations. Mod Pathol 2006;19(Suppl. 1):30A. 324. Banys M, Gruber I, Krawczyk N, et al. Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed